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As populations benefit from increasing lifespans, neu-
rodegenerative diseases have emerged as a critical
health concern. How can the fruit fly, Drosophila mela-
nogaster, contribute to curing human diseases of the
nervous system?A growing number of neurodegener-
ative diseases, as well as other human diseases, are
being modeled in Drosophila and used as a platform
to identify and validate cellular pathways that contrib-
ute to neurodegeneration and to identify promising
therapeutic targets by using a variety of approaches
from screens to target validation. The unique proper-
ties and tools available in the Drosophila system, cou-
pled with the fact that testing in vivo has proven highly
productive, have accelerated the progress of testing
therapeutic strategies inmice and, ultimately, humans.
This review highlights selected recent applications to
illustrate the use of Drosophila in studying neurode-
generative diseases.
Diseases Can Be Modeled in Flies
Many of the classic studies of brain functional genetics
used conventional loss-of-function approaches (Hotta
and Benzer, 1970; Lin et al., 1998; Lush et al., 1998; Min
and Benzer, 1999), whereas more recent studies have
focused on investigating fly homologs of human disease
genes. In 1998, the first transgenic Drosophila model of
a human neurodegenerative disease for spinocerebellar
ataxia 3 (SCA3) was described (Warrick et al., 1998),
closely followed by a transgenic model for Huntington’s
disease (Jackson et al., 1998). Over the past several
years, the use of fly models of human diseases has
emerged at a rapid pace and has significantly contrib-
uted to our growing understanding of the molecular
basis of these diseases (for reviews, see Bilen and Bo-
nini [2005] and Sang and Jackson [2005]). Dominant
gain-of-function (GOF) diseases including the polyglut-
amine-repeat diseases, Parkinson’s disease (PD) (over-
expression of mutant and wild-type a-synuclein), and
tauopathies have been effectively investigated with
transgenic approaches. In addition, Drosophila models
for diseases associated with genetic mutations that
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endogenous proteins such as parkin, presenilin, DJ-1,
and others have emerged. Modeling the dominant dis-
eases is accomplished by ‘‘humanizing’’ a fly to produce
transgenic animals expressing the pathogenic form of
a human disease gene. A binary system is used for this
purpose (Figure 1), and transgenic flies containing a
tissue-specific promoter fused to the yeast GAL4 tran-
scription factor are crossed to flies containing the
gene of interest fused to the yeast upstream activator
sequence (UAS), such that offspring will express the hu-
man disease gene only in selected tissues in a controlled
manner (Brand and Perrimon, 1993; Brand and Dor-
mand, 1995). Typically, expression is driven in neurons
(e.g., elavdriver) or in all cells of the eye (e.g., gmrdriver),
and neurotoxicity is monitored by measuring the loss of
visible photoreceptor neurons in the eye, lethality of the
organism, or behavioral phenotypes (for reviews, see
Bilen and Bonini [2005]; Marsh and Thompson [2004],
and Sang and Jackson [2005]), although many other
measures of degeneration can be used. Transgenes ex-
pressing short hairpin RNAs to interfere with expression
of specific genes also make use of this binary system
(Figure 1). This system allows one to maintain toxic pro-
teins separate from the elements that drive their expres-
sion, thus avoiding the selective pressures that might
lead to the accumulation of modifiers or the selection
of mutated transgenes. This system also allows one to
modulate the levels of transgene expressed by capitaliz-
ing on the temperature dependence of the GAL4 system
(Duffy, 2002).
How Fly Models Can Complement Other Systems
In studying human neurodegenerative diseases, one
typically employs multiple systems, including cell-based
models in which one can generate stably expressing
lines and phenocopy cellular aspects of disease. How-
ever, in many cases, the response of the intact organism
is not fully recapitulated in cell lines. In vitro, intersecting
physiological pathways and responses (e.g., neuro-
transmitter circuitry and interactions with support cells,
etc.) are eliminated, nonautonomous cellular influences
are removed, and new parameters such as those used
to immortalize cells, are often introduced, thus reducing
the ability of cultured cells to mirror in vivo pathology. It
can also be very difficult to obtain a functional measure
of the impact of pathogenic proteins in in vitro systems.
The possibility that cells in culture may represent a sub-
set of cells that do not reflect the diversity of neurons of
the adult brain is illustrated in Drosophila. Challenge of
the Drosophila brain mushroom-body neurons in vivo
with expanded repeat Huntington (Htt) leads to approxi-
mately 25% loss of cells (volume) (Agrawal et al., 2005).
However, dissociation and culturing of those brains
from expressing animals yields cells that have a reduced
plating efficiency in comparison to nonchallenged cells,
although the cells that do become established in culture
show no progressive death when they are compared
to nonchallenged cells plated in parallel (O’Dowd and
J.L.M., unpublished data). It is not clear whether
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170Figure 1. Humanized Flies Express Human Genes in Drosophila with the Binary GAL4/UAS System
Genes can be either mutant disease genes or modifiers of human disease genes.conditions in culture are different from those in vivo or
whether culturing selects a subset of neurons with differ-
ent susceptibilities to pathogenic challenge. In contrast,
although mice and other mammalian model systems
offer in vivo opportunities and extensive similarity to
the human brain, the length of time and cost required
to perform experiments comparable to those possible
in flies can be prohibitive.
Flies, on the other hand, allow excellent genetic ma-
nipulation and in vivo readouts of pathology, and the
pathways are considered generally highly conserved
with vertebrates, with approximately 75% of human
genes known to be associated with disease having a
Drosophila ortholog (Reiter et al., 2001). Drosophila is
emerging as a model animal with broad applications for
rapidly addressing mechanistic questions and testing
therapeutic options because flies can be engineered
to exhibit many of the symptoms of human disease. As
would be expected from mammalian studies, for in-
stance, decreased glutamate buffering in Drosophila is
neurotoxic and provides a genetic system for analysis
of glutamate-mediated neurodegeneration (Rival et al.,
2004). For instance, flies recapitulate characteristic as-
pects of neurodegenerative diseases such as the poly-
glutamine-repeat diseases. Fundamental characteristics
reflected in the fly include polyglutamine length-depen-
dent pathology that is of later onset (late in larval or pupal
stages), is progressive, causes motor abnormalities, and
causes early death (Marsh and Thompson, 2004).
Insights from Flies into Human
Neurodegenerative Diseases
Drosophila has been used to model neurodegenerative
diseases ranging from transgenic models of dominantpolyglutamine-repeat diseases, tauopathies, Alzheimer’s
disease (AD), and Parkinson’s disease (PD) to expanded
triplet-repeat diseases in noncoding DNA (e.g., fmr1,
SCA8). In addition, fly models have been generated to
study autosomal-recessive loss-of-function mutations
that cause familial forms of PD (e.g., DJ-1, parkin, and
PINK1) and AD (e.g., presenilin, APPL) (for reviews, see
Bilen and Bonini [2005]; Sang and Jackson [2005]; Seid-
ner et al. [2006], and Whitworth et al. [2006]). Selected
examples that illustrate how these models can provide
insight into neurodegenerative diseases are described
here.
1. Tauopathy
A key feature of AD and other ‘‘tauopathies’’ is the neu-
rofibrillary tangle, characterized by the accumulation
of hyperphosphorylated tau, but the range of cellular
processes that can impact this process is unclear. Tau
pathology has been effectively modeled in flies (e.g.,
Mudher et al. [2004]; Wittmann et al. [2001]; Karsten
et al. [2006], and Shulman and Feany [2003]), producing
morphologic effects such as axonal degeneration and
swelling. These flies have effectively been used to illus-
trate the involvement of specific pathologic processes,
such as tau phosphorylation, in eliciting these re-
sponses. For instance, tau overexpression in combi-
nation with phosphorylation by the Drosophila GSK-3
ortholog (Shaggy) significantly enhances tau-induced
neurodegeneration and leads to the formation of neuro-
fibrillary pathology (Jackson et al., 2002). Furthermore,
PAR-1 kinase is involved in the tau phosphorylation
process in Drosophila (Nishimura et al., 2004).
2. Ab Toxicity
A second hallmark of AD is the formation of amyloid pla-
ques. Because Drosophila do not have endogenous
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peptide (flies do encode g-secretase components),
several groups have used misexpression of Ab in flies
to recapitulate amyloid-plaque formation in a genetically
tractable model and thus provide models for studying
molecular mechanisms underlying Ab toxicity and iden-
tify potential genetic and pharmacologic modifiers. Tar-
geted expression of Ab42 caused neurodegenerative
phentoypes, amyoid deposits, and learning deficits,
whereas Ab40 expression only caused learning deficits
(Finelli et al., 2004; Iijima et al., 2004), confirming a re-
quirement for the Ab42 peptide in pathology. Using an
alternate approach, Greeve et al. (Greeve et al., 2004)
used targeted expression of APP, the APP-cleaving
enzyme BACE, and presenilins, and this approach also
led to b-amyloid-plaque formation and age-dependent
neurodegeneration. A genetic screen showed that
Drosophila neprilysin 2 suppressed the Ab phenotype
(Finelli et al., 2004), and secretase inhibitors also sup-
pressed neurodegenerative phenotypes (Greeve et al.,
2004), further supporting both the validity of the models
and the modifiers themselves as attractive targets. Wild-
type and arctic mutant peptides of Ab42 were also
expressed in Drosophila; these experiments resulted
in intracellular Ab accumulation, nonamyloid aggre-
gates, progressive locomotor deficits, vacuolation of
the brain, and premature death of flies (Crowther et al.,
2005). Of note, the extent of the neuronal phentoype
was dependent upon the propensity of the expressed
Ab peptide to form oligomers, highlighting the utility of
Drosophila in modeling key aspects of human disease.
3. Parkinson’s Disease
Drosophilamodels of PD underscore the powerful use of
genetics to define pathways that are involved in human
disease as well as the effectiveness of using both trans-
genic and loss-of-function approaches. A number of hu-
man genes have been linked to PD and include domi-
nant mutations in a-synuclein, UCH-L1, and LRRK2 as
well as autosomal-recessive mutations in parkin, DJ-1,
and most recently, PINK1 (for review of fly models of
PD and the corresponding human mutations, see (Bilen
and Bonini, 2005; Sang and Jackson, 2005; Whitworth
et al., 2006). Both gain-of-function and loss-of-function
genetic causes of PD can be modeled in flies. Overex-
pression of either wild-type a-synuclein or mutant forms
associated with human disease leads both to motor
abnormalities and to loss of dopaminergic neurons in
the CNS (Auluck and Bonini, 2002; Feany and Bender,
2000). Loss-of-function mutants of Drosophila parkin
(Greene et al., 2003; Pesah et al., 2004) have been
reported and used to implicate pathogenic mecha-
nisms, including disturbed mitochondrial function. The
recent identification of autosomal-recessive mutations
in Pink1, which encodes a Ser/Thr kinase with a mito-
chondrial-targeting signal associated with PD (Valente
et al., 2004), offered the opportunity to use Drosophila
as the first in vivo model of PINK1 to investigate whether
reduction of PINK1 function could cause PD-like pheno-
toypes and to determine how this model compares to
other loss-of-function models of PD (Clark et al., 2006;
Park et al., 2006; Wang et al., 2006; Yang et al., 2006).
When dPINK1 function is removed, apoptotic muscle
degeneration, defects in mitochondrial morphology, in-
creased sensitivity to oxidative stress, and male sterilitydevelop, and evidence of mitochondrial dysmorphology
is observed (Clark et al., 2006). Similarly, a mitochondrial
basis for dopaminergic neuronal degeneration accom-
panied by locomotor defects and indirect flight-muscle
degeneration was found (Park et al., 2006). Similar phe-
notypes were observed in two further studies (Wang
et al., 2006; Yang et al., 2006). As additional support
for the interchangeability of flies and human systems,
human Pink1 could rescue the fly mutants. Expression
of human SOD1 and antioxidant treatment suppressed
neurodegeneration in these flies (Wang et al., 2006),
again supporting a role for oxidative stress and mito-
chondrial function in the disease. One of the striking as-
pects of these studies was the unexpected finding that
PINK1 and parkin appear to act in a common pathway
that influences mitochondrial integrity; flies lacking par-
kin are nearly identical to flies lacking PINK1, and upre-
gulation of parkin rescued flies lacking PINK1, suggest-
ing that at least some of the genes involved in heritable
forms of PD act through common pathways and identi-
fying a pathway that warrants further investigation as a
therapeutic target. This is a nice example of how genetic
manipulations inDrosophilaprovided insight into a path-
ogenic pathway.
4. SCA1
A critical question for most neurodegenerative diseases
relates to the selectivity observed in regions of the brain
most susceptible to neuronal loss. It is thought that
specific protein interactions may be responsible for the
regional specificity observed. A recent study using Dro-
sophila (Tsuda et al., 2005) suggests that this may be true
for Purkinje cell degeneration through an investigation of
protein interactions with Drosophila ataxin-1 (dAtx-1).
dAtx-1, which does not have the polyglutamine-repeat
domain but does have a conserved AXH domain, inter-
acts through this AXH domain with Drosophila and
mammalian Senseless/GFi-1. When ataxin-1 is overex-
pressed in flies, sensory-organ development is inhibited
as a result of decreased senseless protein, and hAtx-1
overexpression similarly reduces Gfi1 in Purkinje cells.
Significant to the SCA1 purkinje cell phenotype, deletion
of the AXH domain abolishes reduction of Gfi-1, and
targeted reduction of Gfi-1 mimics the SCA1 phenotype.
Similarly, another ataxin-1 interactor, brother of ataxin-1
(Boat), is also reduced in Purkinje cells in mice, and this
ataxin-1 association with Boat can suppress a mutant
ataxin-1-mediated eye defect in flies (Mizutani et al.,
2005).
Other neurodegenerative diseases have been mod-
eled in flies, but those discussed above illustrate several
recent examples of how studies in Drosophila can lead
to the articulation of a pathogenic pathway (PD,
PINK1, and parkin), can provide insight into the mecha-
nisms of selective regional degeneration (SCA-1), and
can help dissect the pathogenic contributions of selec-
tive protein processing products (tau and Ab). One can
expect continuing insights to emerge from Drosophila
studies in other systems.
Strategies for Using Drosophila
Drosophila can be used to devise productive testing
paradigms ranging from genetic screens to target vali-
dation (Figure 2).
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172Figure 2. Schematic of Utility of Drosophila Models of Neurodegenerative DiseaseGenetic-Modifier Screens
The power of Drosophila genetics can be used to con-
duct genetic modifier screens that will identify proteins
and genetically interacting pathways that modulate
pathology. These types of screens were among some
of the first efforts to use fly models of neurodegenerative
diseases to identify pathogenic mechanisms and high-
lighted the importance of heat-shock proteins/chaper-
ones, the protein-degradation machinery, and trans-
criptional regulatory proteins in polyglutamine-repeat
diseases (Fernandez-Funez et al., 2000; Kazemi-Esfar-
jani and Benzer, 2000). Similarly, kinases and phospha-
tases emerged as major modifiers in a genetic-modifier
screen of a Drosophila model of tauopathy with candi-
date tau kinases shown to enhance tau toxicity (Shul-
man and Feany, 2003), as would be anticipated for
diseases associated with phosphorylation of tau. Such
screens can identify pathways that are not necessarily
cell autonomous and that thus could be missed in
screens with cultured cells. Clues to the direct or indirect
nature of identified genetic interactions can then be
found with colocalization studies followed by biochem-
ical studies. Furthermore, if biochemical studies identify
an interacting protein, the involvement of that protein in
a particular pathway can be functionally explored in vivo
by genetically manipulating the identified gene in combi-
nation with other genes in the pathway, so that multiple
gene responses may be used to confirm involvement
of the pathway (e.g., Steffan et al. [2001]). In addition,
suspect genes can be manipulated both by reducing
dose and by increasing dose via overexpression con-
structs. Observing the expected opposite effects on pa-
thology provides encouraging evidence for a bona fide
impact of that activity on pathogenesis. A recent appli-
cation of using a genetic-validation screen in Drosophila
as part of a cross-species functional-genomic approachyielded tau modifiers including puromycin-sensitive
aminopeptidase (PSA/Npepps), which was protective
when overexpressed and deleterious when reduced
(Karsten et al., 2006). These data were further supported
through studies showing that human PSA directly
cleaves tau in vitro.
Hypothesis Testing
As well as being a powerful tool for identifying novel
pathways, Drosophila can be employed in testing spe-
cific hypotheses that arise either from primary genetic
or pharmacologic screening with flies or from studies
in other systems. The facile genetic manipulations that
are available make it possible to rapidly manipulate a
variety of proteins in any given pathway and provide
confirmation that the expected manipulations are rele-
vant as hypothesized. Below, we provide some exam-
ples of hypothesis testing in flies with an emphasis on
polyglutamine-repeat diseases.
Transcriptional Dysregulation. A variety of studies
in mammalian cells and brain tissue have implicated
transcriptional dysregulation in Huntington’s disease
(HD) (Cha, 2000), and subsequent studies have sug-
gested that global transcriptional regulators such as
acetyltransferases might be bound and affected by mu-
tant Htt and other expanded polyglutamine-containing
proteins (Hughes et al., 2001; McCampbell et al., 2001;
Steffan et al., 2001). Through the use of Drosophila, it
was possible to test the explicit hypothesis that reduc-
tion of neuronal histone acetyl transferase activity con-
tributes to pathology in vivo by demonstrating that
inhibition of the counteracting activity, HDACs, either
genetically or pharmacologically, is able to suppress pa-
thology. Subsequent studies in mice confirmed this ob-
servation (Ferrante et al., 2003; Hockly et al., 2003) and
have rapidly led to human trials (Huntington’s Study
Group, http://www.huntington-study-group.org/). Such
Review
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pounds already deemed appropriate for use in humans
(e.g., through safety and tolerability trials) and used clin-
ically for other disorders.
In other non-polyglutamine-repeat applications, gene-
expression profiling in fly models of PD has provided
insight into the temporal pattern of transcriptional dysre-
gulation versus overt neurodegeneration (Scherzer et al.,
2003). These results support a common mechanism of
both PD and polyglutamine-repeat diseases whereby
transcriptional changes are early events in pathogenesis
prior to overt phenotypes.
Chaperones. The pathology-suppressing role that
was suggested for HSPs by studies in cells, flies, and
mice (for review, see Muchowski and Wacker [2005])
was nicely explored both genetically and pharmacolog-
ically in Drosophila, resulting in a potential pharmaco-
logic strategy for PD (geldanamycin) (Auluck and Bonini,
2002; Auluck et al., 2002), and this strategy has subse-
quently been demonstrated to also be an excellent can-
didate strategy for HD (Agrawal et al., 2005). Recent
application to a mouse model of SBMA further supports
the translational promise of initial testing of therapeutic
approaches in flies (Waza et al., 2006).
Axonal Transport. Initial studies suggested that ex-
pression of polyglutamine-repeat proteins in the cytosol
and reduced Htt function cause disruption of axonal
transport in flies (Gunawardena et al., 2003). Again sug-
gesting common mechanisms among neurodegenera-
tive diseases, deletion of the Drosophila homolog of
APP and directed expression of hAPP cause similar ef-
fects (Gunawardena and Goldstein, 2001). To investigate
nonnuclear and nuclear effects of mutant Htt expression
on axonal transport, Lee et al. (Lee et al., 2004) used fly
models that formed cytosolic aggregates (mutant Htt)
and also showed disrupted axonal transport and accu-
mulation of polyglutamine aggregates at synapses. In
contrast, when expanded polyglutamine tracts alone or
those in a SCA3 protein context were expressed, only
nuclear aggregates were observed, with no disruption
of axonal trafficking, suggesting that a combination of
nuclear and nonnuclear events plays a role in HD patho-
genesis. These results are supported by findings in mice
with NLS and NES targeted Htt exon 1 polypeptides
(Benn et al., 2005; Schilling et al., 2004).
Autophagy/ProteinClearance.Clearance of misfolded
proteins is significantly impaired in most of the late-
onset neurodegeneration diseases, and decreased pro-
teasome activity and autophagy have been investigated
(Thoreen and Sabatini, 2004). Ravikumar et al. tested
the hypothesis that mTOR sequestration into polyglut-
amine aggregates is protective by using rapamycin
(a specific mTOR inhibitor) and found that rapamycin
treatment induces autophagy and suppresses neuro-
toxicity in both fly and mouse models of HD (Ravikumar
et al., 2004). Rapamycin was found to also reduce para-
quat toxicity in flies and protect cells against a range
of pro-apoptotic insults (Ravikumar et al., 2006), poten-
tially via the upregulation of autophagy and enhanced
clearance of mitochondria to reduce cytochrome c
release.
Protein Modification. Studies inDrosophila have high-
lighted the role of posttranslational modifications in
affecting pathology and have thus opened a new areafor development of potentially therapeutic interventions.
For example, inhibition of SUMO modification sup-
presses pathology in a Drosophila model of HD (Steffan
et al., 2004); in contrast, in an SBMA model, pathology
caused by expressing an amino-terminal fragment of
the human androgen receptor (hAR) containing an ex-
panded polyglutamine repeat was enhanced by overex-
pression of a mutant Uba2 (activating E1 enzyme)
(Auluck et al., 2002). A role for protein modification is fur-
ther underscored by the observation that 14-3-3 protein
binds to and stabilizes ataxin1. This association is
regulated by AKT phosphorylation, and in flies, both
14-3-3 and AKT modulate neurodegeneration (Chen
et al., 2003).
Protein Function and Quality Control. The influence
of the normal function of the disease protein and the
involvement of protein quality-control pathways, each
central issues in neurodegenerative pathology, have
been linked in studies of SCA3. Human ataxin-3 is a
polyubiquitin-binding protein with ubiquitin protease
activity. The authors show (Warrick et al., 2005) that in
flies this protein suppresses polyglutamine neurode-
generation, which requires the ubiquitin-associated
activities of the protein and proteasome function. These
results also highlight the importance of disease-protein
activity.
Ubiquitination plays a similar role in SCA1 pathogene-
sis, although in this case through an interaction with the
ataxin-1 protein. CHIP (C-terminus of Hsc-70-interact-
ing protein) directly interacts with ataxin-1 and pro-
motes ubiquitination of expanded ataxin-1 in vitro and
in cells (Al-Ramahi et al., 2006). Hsp70, which sup-
presses toxicity in several models of polyglutamine-
repeat disease, increases this CHIP-mediated ubiquiti-
nation. When tested in flies, overexpression of CHIP
suppresses neurotoxicity and decreases mutant ataxin-1
protein levels and thus demonstrates in vivo efficacy.
CHIP was also protective in other fly models of polyglut-
amine-repeat disease but, significantly, did not suppress
toxicity in flies expressing only a polyglutamine-repeat
(127Q) polypeptide in the absence of disease-protein
linkage. These observations suggest common mecha-
nisms among the polyglutamine-repeat diseases with
respect to systems regulating protein function and
quality control.
Mechanisms of Neuronal Loss. Sang et al. (Sang et al.,
2005) assessed the contribution of specific cell-death
regulators in polyglutamine-induced cell death. Deple-
tion of the Drosophila ortholog of Apaf 1 (Dark) dramat-
ically rescues neurotoxicity elicited by expression of
expanded polyglutamine repeats alone or Htt exon1 in
flies. A mechanism suggested by these fly studies is
that Dark facilitates accumulation of polyglutamine
aggregates. Furthermore, expression of expanded poly-
glutamines was found to induce an increase in Dark ex-
pression. A common role for Dark/Apaf 1 across models
and species was suggested by the colocalization of
Apaf-1/Dark with Htt-containing aggregates in flies,
mouse brain, and human brain tissues.
Other Mechanistic Studies. An extensive number of
other investigators have effectively used Drosophila
to focus on mechanisms involving a broad range of cel-
lular processes. These include acceleration of aggregate
nucleation kinetics by nonpathogenic polyglutamine
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174proteins (Slepko et al., 2006), p53 activation (Bae et al.,
2005), EGFR signaling and glutamate transporter func-
tion (Lievens et al., 2005), and the interaction of parkin
and a-synuclein (Haywood and Staveley, 2004; Yang
et al., 2003) as well as the long-term effects of perturba-
tions of ion channels and neuronal membrane excitabil-
ity on the maintenance of neuronal integrity inDrosophila
(Fergestad et al., 2006). The growing number of such
studies underscores the fact that the similarities in fun-
damental cellular mechanisms that affect pathology
between the fly and mammalian systems become more
evident with every passing year.
Chemical-Compound Screens
Just as flies are good candidates for genetic-modifier
screens, they are amenable to large-scale drug screen-
ing, particularly when the screening is automated and
highly controlled for all variables, such as light/dark
cycle, humidity, circadian effects on the assay, age,
and other variables. However, flies, similar to most other
intact organisms, are largely not amenable to ‘‘high-
throughput’’ screening at levels achieved with yeast,
cultured cells, or cell-free systems. However, flies have
been productively employed for modestly high-through-
put screening of chemical-compound libraries (e.g., En-
Vivo pharmaceuticals), for the testing of drugs that tar-
get a particular class of proteins, or for the testing of
compounds in ‘‘secondary assays’’ arising from primary
high-throughput small-molecule drug-discovery efforts
in other systems.
The ability to use flies as a secondary screening assay
for modest throughput testing of drug leads identified in
other assays has proven to be a key strength of the fly
model (e.g., Agrawal et al. [2005]; Apostol et al. [2003];
Ehrnhoefer et al. [2006]; and Zhang et al. [2005]; Figure 3]
and may play a significant role in the drug-discovery
pipeline. An example is the use of flies as a rapid means
of performing preclinical testing of expanded polyglut-
amine-repeat-aggregation inhibitors that were first iden-
tified in yeast, cell culture, or membrane filtration as-
says. Although several inhibitors were found to inhibit
aggregation in these studies, variables such as which
compounds might be tolerated in an intact organism
or might modulate a neurodegenerative phenotype
in vivo could be tested in flies (Desai et al., 2006; Ehrn-
hoefer et al., 2006; Zhang et al., 2005). These studies
led to the identification of new therapeutic targets, in-
cluding several EGFR antagonists (Desai et al., 2006).
Although flies possess a blood-brain barrier with several
similarities (e.g., Daneman and Barres [2005]; Lane and
Swales [1978], and Schwabe et al. [2005]) to the mam-
malian blood-brain barrier, it has proven possible to
test many compounds by simply feeding them to flies.
Using fly models to rapidly identify scaffolds that appear
to be effective in vivo has allowed investigators to focus
attention on some of the most promising leads.
Although in their infancy, other potentially powerful
applications of Drosophila models include in vivo
screening to test analogs of candidate drugs or scaf-
folds. Such testing in vivo has the advantage that it inte-
grates the impact of various analogs on other cellular
components to give a quick read-out of effective versus
noneffective directions for further medicinal chemistry.
Other types of drug testing involve overexpressing a
human target protein to obtain a gain of function pheno-type, which could be lethality or another readily moni-
tored phenotype. Drugs and analogs of hits can then
be screened for suppression of the overexpression
phenotype as a rapid way to select high-potency ana-
logs. Inhibitors that directly target the human protein,
as well as inhibitors that block pathway elements
Figure 3. EGCG Diminishes the Toxicity of Mutant htt Fragments in
Fly Models of HD
(A) Rescue of degeneration of photoreceptor neurons in Drosophila
expressing mutant htt fragments with 93 glutamines. Newly eclosed
flies were kept on food supplemented with different amounts of
EGCG (0.01, 0.1, 1, 10, and 100 mM) or solvent only, and the average
number of photoreceptor cells per ommatidium were scored 7 days
post-eclosion via the pseudopupil technique. Error bars represent6
standard error. Day 0 shows the neuronal loss that has occurred dur-
ing pupal development prior to drug treatment. Values forR0.1 mM
are all significantly different (p < 0.002) from the no-drug control;
0.01 mM EGCG had no significant effect. Maximal rescue in the rep-
resentative experiment shown was 29%.
(B) Representative deep-pseudopupil images of eyes from 7-day-
old EGCG-treated and solvent-treated flies. Left panel: Solvent-
treated flies show extensive degeneration with many ommatidia
containing either three (white arrowhead) or four (yellow arrowhead)
rhabdomeres. Right panel: Flies fed 100 mM EGCG show less degen-
eration; most ommatidia contain 5–6 rhabdomeres, with some re-
taining seven (green arrowhead).
(C) Age-dependent deterioration of climbing abilities in flies ex-
pressing mutant htt fragments with 93 glutamines (UAS-httQ93) in
neurons was monitored by placement of the flies on the bottom of
a vertical glass tube and measurement of the distance covered
within 60 s. Flies mated and raised on food with 500 mM EGCG per-
formed significantly better than solvent-treated controls. From Ehrn-
hoefer et al. [2006], by permission of Oxford University Press.
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175downstream of the transgene, can be detected in this
type of screen (e.g., Bhandari and Shashidhara [2001]).
Target Validation
Target validation is a difficult but significant step in the
effective development of a family of therapeutics for
any disease. Compelling identification of the true in vivo
target for any drug helps to channel efforts to develop
and identify second-generation drugs that are hoped
to be even more effective. Flies offer an opportunity to
assist in this endeavor.
Under the term ‘‘target validation,’’ it is beneficial to
distinguish two levels of target validation. One can ge-
netically validate a target protein by showing that reduc-
tion (or increase) in the activity of a particular gene leads
to a desired affect. In that case, manipulation of the
target gene or protein with drugs may be desirable
[e.g., HDAC inhibitors (Steffan et al., 2001), Hsp90 Inhib-
itors that upregulate Hsp70 (Auluck and Bonini, 2002).
Another level is pharmaceutical validation of a target
protein; this can be accomplished when it can be dem-
onstrated that several structurally distinct chemicals
(scaffolds) known to biochemically target a particular
protein in vitro produce the same desired phenotypic ef-
fect in living material. In one such study, the target was
not validated, and the study suggests that a novel li-
gand-induced function of the polyglutamine hAR mutant
is active in promoting neurodegeneration in SBMA (Fur-
utani et al., 2005). However, such a resource of charac-
terized scaffolds is not always available. In such cases,
a combined genetic and pharmacological approach to
validating a particular protein as the effective target of
a drug in vivo can be useful.
For example, one approach to validating a drug target
involves genetically deleting the target in question (either
through use of characterized mutants or through RNAi
approaches) and demonstrating that the drug has no
effect when the target is removed. Alternatively, one
can demonstrate that the level of drug necessary to
achieve a particular response depends on the dose of
the presumed target gene by using a series of loss-
and gain-of-function mutations and transgenes (e.g.,
Marsh and Wright [1986]). Follow-up studies may include
further ‘‘humanizing’’ the fly by replacing the endoge-
nous target gene with the human homolog and testing
whether the drug is still effective. Although these types
of studies have not yet been highly utilized, they repre-
sent potentially useful areas for further development.
Limitations
What are some of the potential limitations of model or-
ganisms such asDrosophila? To the extent that a patho-
logical response requires the interaction of the patho-
genic protein with other cellular proteins, it is certainly
possible that some of the proteins in Drosophila are dif-
ferent from the putatively interacting proteins in man. In
this case, one could potentially obtain false positive or
negative results of interaction if the human disease pro-
tein cannot interact with a diverged but genuine target
protein in the fly. Remarkably, there are many cases in
which a human protein is able to replace a Drosophila
protein in a pathway as measured by the ability of an ec-
topically expressed human or mammalian protein to res-
cue mutations in fly genes. Examples of interchangeabil-
ity between flies and man include those in the followingreferences: Bhandari and Shashidhara [2001]; Grens
et al. [1995]; Holley and Ferguson [1997]; McGinnis
et al. [1990]; Ross et al. [2001], and Rothba¨cher et al.
[1995]. However, some differences are apparent. For
instance, secretion signals in the fly and in mammalian
systems have diverged for some proteins (Ross et al.,
2001), whereas other secretion signals are recognized
across species.
An apparent lack of neurotrophic factors and neure-
gulins that are structurally related to mammalian factors,
e.g., BDNF, has been described as a limitation to using
flies in studying human neurodegenerative diseases.
These factors are involved in functions such as axon
guidance, targeting, and connectivity. However, a recent
review described cellular, genetic, and functional data
that demonstrate the existence of both neurotrophic
and gliatrophic interactions in the Drosophila nervous
system (Hidalgo et al., 2006) and showed that glial
survival is maintained by the epidermal growth factor
receptor (EGFR) signaling pathway in response to
specific ligands including spitz, a transforming growth
factor-a (TGF-a) signaling molecule, and vein, a neure-
gulin ortholog. The architecture of the fly nervous sys-
tem contains separate specialized functions such as
vision, learning and memory, and olfaction, and the
existence of neuronal trophic factors is predicted by
these similarities.
Conclusions
The range and diversity of studies highlighted here rep-
resent only a fraction of the emerging studies that use
Drosophila to investigate fundamental cellular mecha-
nisms that impact human pathology, from neurodegen-
eration to cardiac rhythm to many other disease states.
These studies demonstrate that the similarities between
fundamental cellular mechanisms that affect pathology
in the fly and mammalian systems are becoming more
apparent with every passing year. The low cost, rapid
generation time, and large repertoire of genetic and
developmental tools available with Drosophila allow fly
studies to speed the progress of identifying promising
therapeutic strategies for testing in mammals.
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